Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
Age and repeat dosing influence VRC07-523LS PK. An 80-mg dose followed by 100 mg at 12 weeks rapidly achieves and maintains concentrations >10 µg/mL for >24 weeks. This dosing strategy is expected to result in antiviral effects in patients with sensitive viruses and supports further evaluation of VRC07-523LS.
Authors
- Dustin Huynh (ORCID: https://orcid.org/0000-0002-0514-0294)
- Gama Lucio
- Petronella Muresan
- Mina Nikanjam (ORCID: https://orcid.org/0000-0001-7052-6348)
- Hans B. C. Spiegel
- Martin R. Gaudinski (ORCID: https://orcid.org/0000-0002-3743-5281)
- Coleen K Cunningham
- Charlotte Perlowski
- E. Capparelli
- Dwight E Yin
- Jack Moye
Institutions
- Family Health International 360 (US)
- Children's Hospital of Orange County (US)
- National Institute of Allergy and Infectious Diseases (US)
- Frontier Science & Technology Research Foundation, Inc. (US)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- University of Montana (US)
- University of Colorado Denver (US)
- Kelly Services (United States) (US)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1093/jac/dkaf449
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00